MAPT and Alzheimer disease: Consistent with CSF levels observed for Tau by immunoassay and TMT-MS (Fig. 1 B and C), the M12 eigenprotein had lower levels in African Americans, compared to Caucasians with AD, albeit not significant (p = 0.055) (Fig. 4B).